Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G.

Circulation. 2005 Jun 14;111(23):3105-11. Epub 2005 Jun 6.

2.

Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.

Zuo XR, Zhang R, Jiang X, Li XL, Zong F, Xie WP, Wang H, Jing ZC.

Am J Cardiol. 2012 Jun 15;109(12):1801-6. doi: 10.1016/j.amjcard.2012.02.026. Epub 2012 Mar 28.

PMID:
22459309
3.

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G.

Eur Respir J. 1998 Aug;12(2):265-70.

4.

Outcomes in children with idiopathic pulmonary arterial hypertension.

Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ.

Circulation. 2004 Aug 10;110(6):660-5. Epub 2004 Aug 2.

5.

Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.

Tonelli AR, Alnuaimat H, Mubarak K.

Respir Med. 2010 Apr;104(4):481-96. doi: 10.1016/j.rmed.2009.11.015. Epub 2009 Dec 8. Review.

6.

Vasodilator therapy for primary pulmonary hypertension in children.

Barst RJ, Maislin G, Fishman AP.

Circulation. 1999 Mar 9;99(9):1197-208.

7.

Recent advances in the treatment of pediatric pulmonary artery hypertension.

Barst RJ.

Pediatr Clin North Am. 1999 Apr;46(2):331-45. Review.

PMID:
10218078
9.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
10.

Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.

Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G, Humbert M, Simonneau G, Sitbon O.

Eur Heart J. 2010 Aug;31(15):1898-907. doi: 10.1093/eurheartj/ehq170. Epub 2010 Jun 11.

PMID:
20543192
11.

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G.

J Am Coll Cardiol. 2002 Aug 21;40(4):780-8.

12.

Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.

Houde C, Bohn DJ, Freedom RM, Rabinovitch M.

Br Heart J. 1993 Nov;70(5):461-8.

13.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.

Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.

Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.

PMID:
20451700
14.

Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension.

Saito Y, Nakamura K, Miyaji K, Akagi S, Mizoguchi H, Ogawa A, Fuke S, Fujio H, Kiyooka T, Nagase S, Kohno K, Morita H, Kusano KF, Matsubara H, Ohe T, Ito H.

J Pharmacol Sci. 2012;120(3):206-12. Epub 2012 Oct 30.

15.

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.

Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS.

Ann Intern Med. 1994 Sep 15;121(6):409-15.

PMID:
8053614
16.

Primary pulmonary hypertension: Current therapy.

Sitbon O, Humbert M, Simonneau G.

Prog Cardiovasc Dis. 2002 Sep-Oct;45(2):115-28. Review.

PMID:
12411973
17.

Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension.

Morales-Blanhir J, Santos S, de Jover L, Sala E, Paré C, Roca J, Rodriguez-Roisin R, Barberà JA.

Respir Med. 2004 Mar;98(3):225-34.

PMID:
15002758
19.
20.

Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.

Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, Simonneau G, Humbert M.

Arthritis Rheum. 2008 Feb;58(2):521-31. doi: 10.1002/art.23303.

Supplemental Content

Support Center